Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTHROID-3 vs COLYTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Hypothyroidism (thyroid hormone replacement therapy),Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
L-T4: 6-7 days; L-T3: 1-2 days. Clinical context: Steady-state achieved in ~6 weeks for T4, ~8 days for T3.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Levothyroxine (T4) is metabolized to liothyronine (T3) via deiodination in peripheral tissues (liver, kidney, etc.). Liothyronine (T3) is metabolized via deiodination and conjugation (glucuronidation and sulfation) in the liver and kidneys. Hepatic enzymes involved include deiodinases (D1, D2) and UDP-glucuronosyltransferases (UGTs).
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Renal (approx. 20-40% as unchanged drug and metabolites), biliary/fecal (approx. 60-80% as conjugated metabolites).
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
99.8% for L-T4 (thyroxine-binding globulin, transthyretin, albumin); 99.7% for L-T3 (same proteins, lower affinity).
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
L-T4: 0.1-0.2 L/kg (mainly intravascular); L-T3: 0.4-0.6 L/kg (broader tissue distribution).
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Oral L-T4: 80-90% (fasting; reduced by food and malabsorption). Oral L-T3: 95-100% (well absorbed).
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
No specific GFR-based dose adjustment required; monitor thyroid function in severe chronic kidney disease (GFR <30 m L/min/1.73 m²) as drug clearance may be reduced.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
No specific adjustment for Child-Pugh class A or B; use with caution in Child-Pugh C due to reduced hepatic conversion, monitor TSH.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Not FDA-approved for children; adult dose not suitable. For hypothyroidism in children, use levothyroxine monotherapy at 25-50 mcg/day for ages 1-3 years, 50-100 mcg/day for ages 3-10 years, and 100-150 mcg/day for ages 10-16 years, adjusted per TSH.
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
Start with lower dose: 25 mcg levothyroxine/7.5 mcg liothyronine (half tablet) orally once daily, titrate slowly every 4-6 weeks based on TSH, due to increased risk of cardiac adverse effects and altered metabolism.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
None
None
Cardiac toxicity (e.g., arrhythmias, angina, myocardial infarction) due to excessive thyroid hormone levels,Thyrotoxic crisis (thyroid storm) if overdosed,Adrenal insufficiency: may precipitate acute adrenal crisis in patients with adrenal insufficiency,Delayed bone maturation in children if overtreated,Interactions with anticoagulants (increased INR), oral antidiabetic agents (hyperglycemia), and catecholamines (sympathomimetic effects)
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Untreated adrenal insufficiency,Thyrotoxicosis (any etiology),Acute myocardial infarction (recent),Hypersensitivity to any component
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
Take on an empty stomach with water. Avoid concurrent intake with high-fiber foods, walnuts, soybean flour, cottonseed meal, or calcium/iron supplements within 4 hours of dosing as they may reduce absorption.
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic risk from exogenous thyroid hormone. Fetal thyroid function develops at 10-12 weeks; prior to that, fetus depends on maternal T4. Overdose may cause fetal thyrotoxicosis. First trimester: maternal hypothyroidism increases risk of miscarriage and neurodevelopmental deficits. Second/third trimester: overtreatment may cause fetal tachycardia and growth restriction. Postpartum: adjust dose to prevent maternal hypothyroidism.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
Excreted in human milk in low amounts. T3 and T4 are endogenous hormones; exogenous administration results in minimal transfer. M/P ratio: not established for Euthroid-3, but for levothyroxine, M/P ratio ~0.001. Considered compatible with breastfeeding when used at recommended doses. Monitor infant for thyroid suppression (rare at maternal therapeutic doses).
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
Pregnancy increases T4 clearance due to increased TBG and placental deiodination. Dose may need to increase by 20-50% as early as 4-6 weeks gestation. Start with increased dose of 30-50% of prepregnancy dose. Adjust based on TSH every 4-6 weeks. Typical dose increase: 30-50% above baseline. Liothyronine component may require adjustment; monitor free T3 if using T3 therapy. Postpartum: reduce dose back to prepregnancy level.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
Euthroid-3 is a combination of liothyronine (T3) and levothyroxine (T4) in a fixed 1:4 ratio. Monitor TSH, free T4, and free T3 levels to avoid iatrogenic hyperthyroidism. Adjust dose cautiously in elderly or cardiac patients. Use with caution in adrenal insufficiency as thyroid replacement can precipitate adrenal crisis.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
Take exactly as prescribed, typically once daily on an empty stomach 30-60 minutes before breakfast.,Do not switch between different thyroid hormone products without consulting your doctor.,Report symptoms of hyperthyroidism (rapid heartbeat, chest pain, heat intolerance, excessive sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Inform all healthcare providers you are taking this medication.,Store at room temperature away from light and moisture.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTHROID-3 vs COLYTE, answered by our medical review team.
EUTHROID-3 is a Thyroid Hormone Replacement that works by EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.. COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTHROID-3 and COLYTE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTHROID-3 is: Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.. The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTHROID-3 and COLYTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTHROID-3 is classified as Category C. Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic ris. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.